Home > Boards > Canadian > Cannabis >

MediPharm Labs Corp. (MEDIF)

Add MEDIF Price Alert      Hide Sticky   Hide Intro
Moderator: crudeoil24, MERCURIAL, Pisd, MADDSTACKER, Sunblazers, Dude1967
Search This Board: 
Last Post: 5/25/2019 6:37:06 PM - Followers: 56 - Board type: Free - Posts Today: 0


Image result for medipharm labs 

Specialize in cannabis extraction...

https://twitter.com/MediPharmLabs                    https://www.medipharmlabs.com/

Image result for medipharm labs




MediPharm Labs Announces Addition to $1.2B MJ ETFMG Alternative Harvest ETF (USA)
Tuesday 21 May 2019

MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce its addition to the MJ ETFMG Alternative Harvest ETF (NYSE:MJ) (the “Fund”) with approximately US$1.22 billion in assets currently under management.

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the ACMPR without first receiving a cannabis cultivation license. This expert focus on cannabis concentrates begins in its purpose-built laboratory designed to incorporate cGMP (current Good Manufacturing Practices) work flow and ISO standard-built clean rooms and critical environments, allowing MediPharm Labs to produce purified, pharmaceutical-like cannabis oil and concentrates for advanced derivative products. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream extraction methodologies and purpose-built facilities to deliver pure, safe and precisely-dosed cannabis products to patients and consumers. MediPharm Labs’ private label program is a high margin business for the company, whereby it opportunistically procures dry cannabis flower and trim from its numerous product supply partners, to produce cannabis oil concentrate products for resale globally on a private label basis.

Image result for medipharm labsImage result for medipharm labsImage result for medipharm labs


TORONTO, May 22, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce it has been selected by The Mount Sinai Hospital, New York City (“Mount Sinai”), to participate in a clinical trial dedicated to developing a non-addictive oral gelcap medication for the treatment of opioid use disorder through anti-anxiety intervention utilizing hemp-derived CBD combined with a proprietary formula (the “Formula”). This will be a U.S. and international large-scale, multi-site clinical trial that will include at least 500 patients spanning the United States, Canada, Australia, Europe and Jamaica.

The clinical trial will be led by renowned principal researcher, Dr. Yasmin L. Hurd, PhD, the Ward-Coleman Chair of Translational Neuroscience at the Icahn School of Medicine at Mount Sinai, New York City, and Director of the Center for Addictive Disorders for the Mount Sinai Behavioral Health System.

MediPharm Labs is also pleased to be involved in the clinical trial, directed by Mount Sinai, with Courtney Betty of Timeless Herbal Care Inc. (“Timeless Herbal”), a fully integrated licensed producer of medicinal cannabis in Jamaica.  MediPharm Labs will be the exclusive manufacturer of a proprietary hemp-derived CBD oral gelcap medication utilizing the Formula provided by Timeless Herbal for all phases of the clinical trials related to this study that will allow researchers to test an investigational product containing CBD active ingredient.

MediPharm Labs and Timeless Herbal will jointly own any intellectual property developed during the clinical trials (“Developed IP”), excluding the Formulation, and MediPharm Labs will be the exclusive manufacturer for products resulting from this study.

“We are extremely pleased MediPharm Labs has been selected to be involved in this landmark, clinical trial to properly evaluate the potential benefits of CBD and that can lead to important medical therapies for millions suffering from opioid use disorder,” said Patrick McCutcheon, CEO, MediPharm Labs. “We are committed to providing consistent, high quality, pharma-like active ingredients to support advancements in scientific CBD drug development.”

“I am proud to be collaborating with MediPharm Labs, a valuable partner who exemplifies true commitment to research and supporting rigorous scientific research on the potential medical uses of CBD,” said Dr. Yasmin Hurd, Mount Sinai Hospital. “MediPharm Labs was selected as our preferred provider to participate in this critical study largely based on its team’s deep experience in pharma and clinical research, and ability to execute and provide safe, effective and precisely doseable, high quality products.”

Dr. Hurd continued, “The vast number of lives lost, societal burdens and marked health toll caused by opioid addiction continues to grow worldwide and requires bold and unique actions to curb this tidal wave of the opioid epidemic. This consortium strategy is founded on results from established clinical trials that now give us an important opportunity to further advance scientific research in large populations. This is a critical path for the development of true CBD medicinal products that meet FDA approval to treat opioid addiction.”

The arrangement remains subject to MediPharm Labs, Mount Sinai and Timeless Herbal entering into a clinical trial agreement, MediPharm Labs and Timeless Herbal entering into a separate intellectual property agreement and certain regulatory approvals.

MAY 17, 2019

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has shipped 6,000 40 ml units of its SYNC 25 CBD oil to the British Columbia Liquor Distribution Branch (BCLDB). The Emerald-branded pure CBD oil offers consumers a non-THC, smoke-free product alternative.
“We are pleased to offer our new Emerald-branded wellness product SYNC 25 to the recreational marketplace in British Columbia,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “The introduction of SYNC 25 marks the next step in our product growth strategy to develop innovative and quality consumer products that respond to a growing demand while providing higher profit margins.”

The SYNC 25 CBD oil product was extracted by MediPharm Labs Inc., a wholly-owned subsidiary of MediPharm Labs Corp. (TSXV: LABS; OTCQX: MEDIF) (“MediPharm Labs”).

May 15, 2019

MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc. (“MediPharm”), has signed a committed term sheet for a $20 million senior secured revolving credit facility ("Credit Facility") from a Canadian Schedule 1 Bank. The Credit Facility is intended to provide MediPharm Labs access to non-dilutive capital to fund planned growth, as well as for general corporate and working capital purposes.
The Credit Facility consists of a $15 million operating loan with a one-year term and a $5 million non-revolving equipment term loan with a three-year term. The Credit Facility, once closed, will bear interest at the Schedule 1 Bank’s prime lending rate plus 1.85% per annum.

“This commitment marks yet another important milestone that will provide access to non-dilutive capital to support our plans for accelerated growth as we continue to ramp up operations ahead of expected legalization of broader concentrate-based products this fall,” said, Patrick McCutcheon, CEO, MediPharm Labs. “We are pleased to have a leading financial institution support MediPharm Labs as we continue to innovate and expand our private and white label offerings to serve a growing demand for high-quality, adult-use and medical cannabis products.”

14 MAY 2019

Cronos Group and MediPharm Labs Enter Additional Multi-Year Tolling Arrangement

TORONTO, May 14, 2019 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), is pleased to announce that it has entered into a multi-year supply agreement with MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (“MediPharm Labs”).

MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months. In addition, Cronos Group and MediPharm Labs have entered into a multi-year tolling agreement, where Cronos Group will supply bulk cannabis to MediPharm Labs’ state of the art extraction facility in Barrie, Ontario, to fulfill certain additional processing needs of the Company.


Key Q1 2019 Financial and Year-to-Date Highlights

-Revenue of $22 million, a 115% increase over Q4 2018, leading the Canadian cannabis extraction-only industry
-Gross Profit of $6.9 million, Gross Margin 31%
-Adjusted EBITDA of $4.3 million, a 102% increase over Q4 2018, Adjusted EBITDA margin of 20%
-Strong, positive cashflows from operations
-Q1 revenue includes $7.6 million revenue for initial shipment of large private label cannabis oil contract with a large Licensed Producer
-Acquired more than 5,000 kg (or 5 million grams) of dried cannabis in last 2 weeks of Q1 from multiple Licensed Producers to fulfill robust demand for private label offerings
-Continued significant capital investment, further increasing scale of operations to enhance efficiencies through automation, increase throughput capacity and new equipment for diversified product lines including distillates, vapeables, softgel caps and bottled cannabis oil
-Received over $7 million in cash proceeds from warrant exercises subsequent to March 31, 2019

  • reprinted here: 

2018 was a breakthrough year for MediPharm Labs. We became the first fully Licensed Producer to specialize solely in extraction and quickly scaled operations to emerge as the dominant market leader in the manufacturing of high quality, pharmaceutical-like production of cannabis derivative products – the future of cannabis

Image result for medipharm labsImage result for medipharm labsImage result for medipharm labsImage result for medipharm labs


As leading extraction specialists, we demonstrated our ability to rapidly expand our footprint and achieve significant revenue and positive operating cash flow just weeks after receiving our sales License, and our strong operations have continued into 2019. The strength of this performance validates our uniquely focused strategy and investments. We are proud that the MediPharm Labs team stands out among the top global players in the cannabis industry producing tangible results with significant future potential.


2019 Year-to-Date Highlights

  • Executed Private Label Sales Agreements in place valued in excess of $85 million over 15-month period from December 2018
    Executed large Private Label cannabis oil sale for $35 million with additional $13.5 million purchase option over 13-month period
    Signed a 3-year Tolling Agreement with TerrAscend Corp.
    First extraction only LP to sign an International Private Label Sale Agreement with AusCann Group Holdings Ltd. – Export of cannabis oil from Canada to Australia for the manufacturing of hard-shell cannabinoid capsules
    Launched White Label Solutions Platform to extract, purify, formulate, process and distribute for LP’s, direct-to-consumer brands and non-cannabis consumer packaged goods (CPG) companies for provincial distribution
    Signed first White Label agreement to formulate, process and distribute tincture bottles on behalf of an existing brand commencing H2 2019
    Acquired over 5,000 KG of dried cannabis for Private Label cannabis oil production in final two weeks of March
    Initiated trading on OTCQB under symbol “MLCPF” and FSE under symbol “MLZ”


(Mr. McCutcheon continued)... “Looking ahead, we are now working on an ambitious, well-planned agenda for 2019 that will enable MediPharm Labs to extend our first-mover advantage. We are ramping up production, adding capacity, targeting EU GMP certification, expanding product offerings, developing R&D and IP, signing new sales agreements, and executing on our M&A and international growth pipeline.”

“Most importantly, we see all of this as a starting point. We expect to accelerate our growth globally as the size of our addressable market increases and we strengthen our foothold domestically with the expected legalization of vapeables, edibles, beverages and topicals providing a strong growth trajectory in Canada. We will continue to capitalize on the numerous opportunities available to us through effective capital deployment and continued expert execution to create shareholder value for the long term.”

2019 Strategic Priorities

  1. Forge additional domestic and International sales and supply agreements – Utilizing a first-mover and other proprietary advantages, the Company is focused on procuring cost efficient, bulk dried cannabis supply, increasing wholesale Private Label cannabis concentrate (crude resin and distillate) production and value-added products, services and tolling to win new business domestically and internationally.
    Expand White-Label Solutions Platform Including Formulation, Processing and Distribution Services – Expected legalization of vapeables, edibles, beverages and topicals in October 2019 is also expected to expand the Company’s addressable market and act as a catalyst to encourage a broad array of direct-to-consumer brands and non-cannabis consumer packaged goods companies to seek partners like MediPharm Labs for formulation, processing and provincial distribution.
    Increase cGMP Production Capacity – The Company is on track with the installation and commissioning of 2 additional primary extraction lines at its Barrie facility that are expected to increase annual processing capacity to 250,000 kg over a total of 7 extraction lines. Utilizing cGMP methodology, multiple extraction lines provide flexibility to dedicate to specific customer batches and significantly enhance productivity. Flexibility over multiple extraction lines will be transformative, providing a continued competitive advantage in the cannabis market.
     Achieve European Union GMP Certification at Barrie Facility – Expect to achieve certification in the H2 2019 enabling the Company to serve substantial European demand.
    Complete First International Facility in Australia – Australian centre of excellence is expected to be commissioned in H2 2019, pending licensing, and will act as hub to access Asia-Pacific regions.  The facility is designed to produce to cGMP standards with annual extraction capacity of approximately 75,000 kg of dried cannabis. The Australia region provides a strong backdrop for cultivation given more favorable farming conditions where the Company expects to procure locally sourced lower-cost supply inputs for production.
    Expand Secondary Extraction Capabilities – Advancing industrial-scale distillation and commercial chromatography capabilities to produce active pharmaceutical ingredients that require cannabinoid purity of at least 99.9%.  Development is underway for specialized, proprietary chromatography processing with trials to commence H2 2019.
    M&A and Joint Venture Opportunities – The Company has established a robust pipeline of opportunities to replicate its unique business model in other jurisdictions and complementary acquisitions to further enhance and accelerate organic growth.

2018 Financial Highlights

All dollar amounts are expressed in Canadian dollars unless otherwise stated.

¹Adjusted EBITDA is not a recognized performance measure under IFRS, does not have a standardized meaning and therefore may not be comparable to similar measures presented by other issuers. Adjusted EBITDA is included as a supplemental disclosure because Management believes that such measurement provides a better assessment of the Company’s operations on a continuing basis by eliminating certain non-cash charges and charges or gains that are nonrecurring. Adjusted EBITDA is defined as net loss excluding interest, taxes, depreciation and amortization, and share-based compensation and listing expense. Adjusted EBITDA has limitations as an analytical tool as it does not include depreciation and amortization expense, interest income and expense, taxes, share-based compensation and transaction fees. Because of these limitations, Adjusted EBITDA should not be considered as the sole measure of the Company’s performance and should not be considered in isolation from, or as a substitute for, analysis of the Company’s results as reported under IFRS. The most directly comparable measure to Adjusted EBITDA calculated in accordance with IFRS is operating income (loss). The above is a reconciliation of the Company’s operating loss to Adjusted EBITDA. See “Reconciliation of non-IFRS measures” in the Company’s Management’s Discussion and Analysis for the year ended December 31, 2018 additional information.



Image result for models and lamborghinisImage result for stock market cannabis moneyImage result for hooker party

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1567  Sticky Note Investor Presentation May 2019 MERCURIAL 05/23/19 11:39:18 AM
#1412  Sticky Note Cronos Group and MediPharm Labs Enter $30 Million MADDSTACKER 05/14/19 11:00:57 AM
#1355  Sticky Note @MediPharmLabs for taking the #4 spot on the Dude1967 05/10/19 06:11:03 PM
#1318  Sticky Note Excellent > up 200%+ YTD. crudeoil24 05/10/19 12:03:22 PM
#1590   https://seekingalpha.com/article/4266330-need-know-cronos-medipharm-deal Wh Pugetsounder1 05/25/19 06:37:06 PM
#1589   Great article, great exposure! otclife 05/25/19 12:07:19 PM
#1588   So why are we back to trading below ztockings 05/24/19 01:31:13 PM
#1587   Nice day never should have sold off that MADDSTACKER 05/24/19 12:32:13 PM
#1586   Nice write-up! The market's going to figure it MERCURIAL 05/24/19 11:17:11 AM
#1585   Thanks great article and informative Mrone 05/24/19 10:39:33 AM
#1584   GREAT article imo ... Pisd 05/24/19 09:22:23 AM
#1583   https://www.fool.ca/2019/05/23/little-known-cannabis-stock-outperforms-canopy-gr Pugetsounder1 05/24/19 09:17:31 AM
#1582   Working on ibox to help educuate new peeps MEDIF$$... Pisd 05/24/19 09:12:11 AM
#1581   “We are extremely pleased MediPharm Labs has been crudeoil24 05/24/19 07:50:30 AM
#1580   You are good to go my friend. Red Sunblazers 05/23/19 09:02:48 PM
#1579   The market’s gonna do what it’s gonna do. MERCURIAL 05/23/19 07:43:31 PM
#1578   New pr out , a little more info MADDSTACKER 05/23/19 07:22:27 PM
#1577   Just bought 200 more of MEDIF at 4.66 DD800 05/23/19 01:25:19 PM
#1576   Gtfoh $2 a share u wish MADDSTACKER 05/23/19 01:08:01 PM
#1575   We can put a plug in this now Dude1967 05/23/19 12:32:43 PM
#1574   Me either, this still has $10 written all otclife 05/23/19 12:28:11 PM
#1573   Yes sir! Posted link earlier but somehow left MERCURIAL 05/23/19 11:57:57 AM
#1572   Trading on OTCQX or Nasdaq, brings on huge crudeoil24 05/23/19 11:57:33 AM
#1571   Nice thank you MADDSTACKER 05/23/19 11:55:57 AM
#1570   Yep Dude1967 05/23/19 11:55:43 AM
#1569   Getting time to load up again! Skynyrd 05/23/19 11:54:13 AM
#1568   Heavy focking power washing today Dude1967 05/23/19 11:54:08 AM
#1567   Investor Presentation May 2019 MERCURIAL 05/23/19 11:39:18 AM
#1566   I'm not selling for shit ... MADDSTACKER 05/23/19 11:20:05 AM
#1565   So many positive catalysts at work here. MEDIF. crudeoil24 05/23/19 10:31:19 AM
#1563   Exactly. Vault is filled with shares, not going MERCURIAL 05/23/19 09:54:03 AM
#1562   This stock is very much subdued...unfortunately. It's ztockings 05/22/19 06:30:04 PM
#1561   Love ya, Thanks for all you bring to Skynyrd 05/22/19 11:47:09 AM
#1560   Why does this concern you , the company MADDSTACKER 05/22/19 11:45:24 AM
#1559   https://www.newcannabisventures.com/top-33-revenue-generating-cannabis-stoc deswag 05/22/19 11:31:45 AM
#1558   I'm not sure I have the ideas you MERCURIAL 05/22/19 11:30:39 AM
#1557   excluding the Formulation this is what concerns me Skynyrd 05/22/19 11:04:19 AM
#1556   MediPharm to Support Major Opioid Addiction Clinical Study wsstocks 05/22/19 10:50:35 AM
#1555   MediPharm Labs and Timeless Herbal will jointly own MERCURIAL 05/22/19 10:49:34 AM
#1554   Thanks gents!!! Now let's make some money !!! MADDSTACKER 05/22/19 10:36:28 AM
#1553   Yes sir AMIGOS MADDSTACKER 05/22/19 10:35:32 AM
#1552   Wonder who the company will be that manufacturers Skynyrd 05/22/19 10:34:20 AM
#1551   Yes he did. Glad I got here too Ihal 05/22/19 10:33:36 AM
#1550   Going to be fantastic bro can't wait glad MADDSTACKER 05/22/19 10:30:25 AM
#1549   Agreed but it should tolerate any Summer slowdown MERCURIAL 05/22/19 10:29:46 AM
#1548   $10.00+ coming, but it takes time for news crudeoil24 05/22/19 10:29:40 AM
#1547   Long live Stacker! Will be cannabis stock TheMonolith 05/22/19 10:26:37 AM
#1546   Hell yea great call again Maddman bwhaha MrCheap 05/22/19 10:26:18 AM
#1545   Sup road warrior! Gonna be a fun ride here! MERCURIAL 05/22/19 10:25:35 AM
#1544   “”clinical trial dedicated to developing a non-addictive oral MrCheap 05/22/19 10:25:21 AM
#1543   Bwaahahaa! Stacker called this one before U.S. started MERCURIAL 05/22/19 10:24:00 AM
#1542   Wooo Hooooo MrCheap 05/22/19 10:22:04 AM
#1541   Let's gooo ihal !! MADDSTACKER 05/22/19 10:20:55 AM
#1540   Congratulations Medipharm fam! Ihal 05/22/19 10:20:26 AM